Gilead Sciences, Inc. (GILD) Position Lessened by Strs Ohio

Strs Ohio trimmed its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 6.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 875,659 shares of the biopharmaceutical company’s stock after selling 57,333 shares during the quarter. Strs Ohio owned 0.07% of Gilead Sciences worth $67,609,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. Bank of New York Mellon Corp increased its position in shares of Gilead Sciences by 11.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 30,936,970 shares of the biopharmaceutical company’s stock worth $2,191,575,000 after purchasing an additional 3,221,439 shares during the last quarter. Northern Trust Corp increased its position in shares of Gilead Sciences by 2.0% during the 2nd quarter. Northern Trust Corp now owns 16,823,192 shares of the biopharmaceutical company’s stock worth $1,191,754,000 after purchasing an additional 325,246 shares during the last quarter. Sanders Capital LLC increased its position in shares of Gilead Sciences by 7.0% during the 2nd quarter. Sanders Capital LLC now owns 10,579,575 shares of the biopharmaceutical company’s stock worth $804,126,000 after purchasing an additional 696,200 shares during the last quarter. Boston Partners increased its position in shares of Gilead Sciences by 3.1% during the 2nd quarter. Boston Partners now owns 8,290,507 shares of the biopharmaceutical company’s stock worth $587,300,000 after purchasing an additional 245,805 shares during the last quarter. Finally, OppenheimerFunds Inc. increased its position in shares of Gilead Sciences by 0.3% during the 2nd quarter. OppenheimerFunds Inc. now owns 7,038,387 shares of the biopharmaceutical company’s stock worth $498,599,000 after purchasing an additional 22,916 shares during the last quarter. 78.06% of the stock is owned by hedge funds and other institutional investors.

Shares of GILD traded down $0.91 during midday trading on Friday, hitting $73.26. The company had a trading volume of 413,620 shares, compared to its average volume of 6,568,269. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.92 and a current ratio of 3.00. The stock has a market capitalization of $98.03 billion, a PE ratio of 8.72, a PEG ratio of -3.84 and a beta of 1.01. Gilead Sciences, Inc. has a 1 year low of $64.27 and a 1 year high of $89.54.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, July 25th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.56 by $0.35. The business had revenue of $5.65 billion during the quarter, compared to analysts’ expectations of $5.20 billion. Gilead Sciences had a return on equity of 41.57% and a net margin of 9.52%. The business’s quarterly revenue was down 20.9% compared to the same quarter last year. During the same quarter last year, the business posted $2.56 EPS. Analysts predict that Gilead Sciences, Inc. will post 6.56 EPS for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 27th. Stockholders of record on Friday, September 14th were paid a $0.57 dividend. This represents a $2.28 annualized dividend and a dividend yield of 3.11%. The ex-dividend date was Thursday, September 13th. Gilead Sciences’s payout ratio is presently 26.64%.

A number of analysts recently issued reports on GILD shares. ValuEngine raised Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Tuesday, July 3rd. BidaskClub upgraded Gilead Sciences from a “strong sell” rating to a “sell” rating in a report on Tuesday, June 26th. Mizuho set a $94.00 target price on Gilead Sciences and gave the company a “buy” rating in a report on Tuesday, July 31st. Wells Fargo & Co raised their target price on Gilead Sciences from $89.00 to $95.00 and gave the company an “outperform” rating in a report on Thursday, July 26th. Finally, Cantor Fitzgerald initiated coverage on Gilead Sciences in a report on Monday, October 1st. They set an “overweight” rating and a $87.00 target price for the company. Eleven analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $88.24.

In other news, Director John C. Martin sold 50,000 shares of Gilead Sciences stock in a transaction dated Tuesday, September 4th. The stock was sold at an average price of $74.16, for a total value of $3,708,000.00. Following the completion of the transaction, the director now owns 3,067,762 shares in the company, valued at approximately $227,505,229.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold a total of 150,000 shares of company stock valued at $11,502,500 in the last quarter. Company insiders own 1.30% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

Further Reading: What is the Dow Jones Industrial Average (DJIA)?

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply